Day: March 20, 2025

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026 TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejection Fraction (“HFrEF”) in March 2025 Cash and cash equivalents of $141.2 million as of December 31, 2024 and February 2025 private placement gross proceeds of approximately $185.0 million, together expected to provide a cash runway into Q4’28WATERTOWN, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”),...

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of approximately $47.6 million from private investment in public equity (PIPE) financing – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2024 and provided a summary of recent pipeline and corporate highlights. “With initial data from the clinical trial of SENTI-202, we are getting a glimpse into the potential profile...

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2024. “In 2024, we prepared our RAS-targeting franchise to enter the...

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Written by Customer Service on March 20, 2025. Posted in Earnings Releases And Operating Results.

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweight Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removed Phase 2a dosing extended to 52 weeks to enhance long-term safety, tolerability, and efficacy data Cash runway projected through at least Q1 2027SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024, along with key accomplishments and upcoming milestones. “Skye’s...

Oxbridge Re Announces 2024 Fourth Quarter Results on March 26, 2025

Written by Customer Service on March 20, 2025. Posted in Public Companies.

GRAND CAYMAN, Cayman Islands, March 20, 2025 (GLOBE NEWSWIRE) — Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the “Company”), which together with its subsidiaries is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities, and reinsurance business solutions to property and casualty today, announced that it plans to hold a conference call on Wednesday March 26, 2025 at 4:30 p.m. Eastern Time to discuss results for the fourth quarter and year ending December 31, 2024. Financial results will be issued in a press release after the close of the market on the same day. Oxbridge Re’s management will host the conference call, followed by a question and answer period. Interested parties can listen to the live presentation by dialing the listen-only number below.Date:...

Toll Brothers Announces Opening of Enclave at Kelsey Creek Luxury Home Community in Bellevue, Washington

Written by Customer Service on March 20, 2025. Posted in Public Companies.

BELLEVUE, Wash., March 20, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, announced its latest Seattle-area community, Enclave at Kelsey Creek, is now open in Bellevue, Washington. The community offers an intimate setting surrounded by 17 acres of green space and is conveniently located near top employers, local shops, and prestigious schools. The first homes are under construction in this boutique community of only 11 homes with anticipated move-in dates for fall 2025. Toll Brothers is hosting an exclusive Hard Hat Tour on Sunday, April 6 from 1:00 p.m. to 3:00 p.m. at 12 148th Ave. NE in Bellevue.Enclave at Kelsey Creek features sophisticated three-story home designs ranging in size from 2,864 to 3,019+ square feet, with 4 bedrooms, 3.5 baths, and 2-car garages. The homes...

Oportun Comments on Letter from Findell Capital

Written by Customer Service on March 20, 2025. Posted in Public Companies.

SAN CARLOS, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Oportun (Nasdaq: OPRT), a mission-driven financial services company, today issued the following statement regarding a public letter from Findell Capital Management LLC (“Findell”): Oportun’s management team and Board of Directors maintain consistent and open dialogue with our shareholders and welcome constructive feedback. We have engaged actively, repeatedly and in good faith with Findell for some time, striving to foster a constructive and collaborative relationship, with the goal of enhancing value for all shareholders. The Board and management have driven significant improvements in Oportun’s performance by taking decisive action to refine the Company’s product portfolio, streamline costs, strengthen its capital position and boost profitability. At the same time, we have...

Sticker Mule’s Suite of Bots Take Over X as Acquisition Proves Successful

Written by Customer Service on March 20, 2025. Posted in Mergers And Acquisitions.

Sticker Mule’s X BotsMonthly engagement for Sticker Mule’s X Bots is skyrocketing.AMSTERDAM, N.Y., March 20, 2025 (GLOBE NEWSWIRE) — Sticker Mule, the Internet’s hottest printing company, has launched a suite of automated X bots. The bots help users print, frame, and edit images by replying to X posts. Sticker Mule entered the X bot space in June 2024 with its $100,000 acquisition of Pikaso, the most popular bot on X, which boasts nearly 1 million followers and 100 million monthly impressions. Pikaso turns X posts into shareable screenshots and continues to enjoy rapid growth. The bot continues to gain more than 25,000 followers per month with a 32% month-over-month increase in impressions. Pikaso was shut down completely at the time of the acquisition. X had implemented new API fees, and the indie company...

SCOR SE announces the availability of its 2024 Universal Registration Document

Written by Customer Service on March 20, 2025. Posted in Public Companies.

Press release20 March 2025 – N° 04 SCOR SE announces the availabilityof its 2024 Universal Registration Document The 2024 Universal Registration Document of SCOR SE (“SCOR” or the “Company”) prepared in ESEF format (European Single Electronic Format) was filed with the French Autorité des marchés financiers (“AMF”) on Thursday 20 March 2025 under number D.25-0124. This document is available on the website of the Company www.scor.com and the website of the AMF www.amf-france.org. Hard copies of the 2024 Universal Registration Document are also available at SCOR’s headquarters, located at the following address: SCOR SE5, avenue Kléber75795 Paris Cedex 16France The 2024 Universal Registration Document includes the following information:the 2024 annual financial report including the report of the board of directors on corporate governance...

Volatus Aerospace Partners with RigiTech to Enhance Medical Delivery Services with Long-Range Drone Technology

Written by Customer Service on March 20, 2025. Posted in Public Companies.

TORONTO, March 20, 2025 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A3DP5Y) (“Volatus” or “the Company”), a leading provider of aerial solutions, is excited to announce a new strategic partnership with RigiTech, a Swiss-based drone technology company. This collaboration aims to integrate RigiTech’s Eiger long-range delivery drone into Volatus’ expanding drone delivery network, significantly enhancing its medical delivery capabilities across Canada and beyond. The Eiger drone is known for its robust, tested design capable of carrying 3 kg payloads for up to 100 km. Equipped with advanced avionics and a safety recovery parachute, the Eiger is ideally suited for the longer-range delivery requirements of Volatus’ medical delivery services. “Integrating RigiTech’s...

Day: March 20, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals